Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7$73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial guidance of$12.0 million New Drug Application for rosacea treatment candidate DFD-29 accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Ma ...